Bonree Health completes A+ round of financing, led by Sunrise Venture
1min read Recently, Shenzhen Borujen Pharmaceutical Co., Ltd. (hereinafter referred to as "Borujen") successfully completed a few million A+ financing, led by Shenzhen Capital Venture Capital, and followed by Zhongchuang Venture Capital and Tsinghua Venture Capital.
Borujen is an innovative pharmaceutical research and development company based on innovative research and guided by clinical needs. The company is committed to the development of innovative drugs and diagnostic methods in the central nervous system (CNS) field, with a pipeline of small molecule oral drugs targeting new targets and radioactive drugs for clinical diagnosis, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company has R&D management teams and technology transfer centers in Shanghai and Shenzhen.
The company's independently developed 1st-class innovative drug BrAD-R13 tablets has obtained clinical trial approval from the US FDA and the National Medical Products Administration of China, and is the first small molecule TrkB receptor agonist to enter the clinical stage, intended for the treatment of mild to moderate Alzheimer's disease. It is currently undergoing a phase I clinical trial. Another independently developed early diagnosis of Parkinson's disease [18F]-F0502B has completed preclinical validation and published data in the top journal Cell, which has been fully recognized and has the potential to become the world's first diagnostic nuclear medicine targeting α-synuclein and serve as the objective gold standard for clinical diagnosis of Parkinson's disease. It is currently undergoing a researcher clinical trial.
Borujen said in the future that it will continue to adhere to the concept of "Borujen" and work closely with research institutions to promote the clinical trial research of innovative drugs in a scientific and efficient manner, make original world-first new drugs in China and industrialize them, and benefit the Chinese and world people.
